Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Neurofibromatosis 2”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Active Not RecruitingNCT05521048
What this trial is testing

Doxycycline in Cutaneous Schwannoma (NF2)

Who this might be right for
Neurofibromatosis Type 2
Massachusetts Eye and Ear Infirmary 19
Not applicableStudy completedNCT02298270
What this trial is testing

Resiliency Training for Patients With Neurofibromatosis Via Videoconferencing With Skype

Who this might be right for
NeurofibromatosisNeurofibromatosis INeurofibromatosis 2+1 more
Massachusetts General Hospital 65
Not applicableUnknownNCT04890132
What this trial is testing

Vestibular Precision: Physiology & Pathophysiology

Who this might be right for
Vestibular SchwannomaInner Ear DiseaseDizziness+2 more
Massachusetts Eye and Ear Infirmary 90
Early research (Phase 1)Study completedNCT02102256
What this trial is testing

A Safety Study of the Auditory Brainstem Implant for Pediatric Profoundly Deaf Patients

Who this might be right for
Profound Bilateral Deafness Due toBilateral Cochlear AplasiaBilateral Cochlear Nerve Deficiency+1 more
Laurie Eisenberg 10
Testing effectiveness (Phase 2)Looking for participantsNCT05253131
What this trial is testing

Trial of Selumetinib and Bromodomain Inhibitor With Durvalumab for Sarcomas

Who this might be right for
MPNSTNF1Sarcoma
University of Alabama at Birmingham 41
Early research (Phase 1)Study completedNCT02955472
What this trial is testing

Bioequivalence Study of Two Formulations of Pregabalin CR (Controlled-release) Table 150 mg

Who this might be right for
Healthy
GL Pharm Tech Corporation 24
Not applicableStudy completedNCT02811718
What this trial is testing

Resiliency Training for Patients With NF2 Via Videoconferencing With Skype

Who this might be right for
Neurofibromatosis 2
Massachusetts General Hospital 45
Not applicableActive Not RecruitingNCT06175637
What this trial is testing

Observational Study to Evaluate the Effect and Safety of Selumetinib in Pediatric Patients With NF1-PNs

Who this might be right for
Neurofibroma, Plexiform
AstraZeneca 409
Testing effectiveness (Phase 2)Study completedNCT03989115
What this trial is testing

Dose-Esc/Exp RMC4630 & Cobi in Relapsed/Refractory Solid Tumors & RMC4630& Osi in EGFR+ Locally Adv/Meta NSCLC

Who this might be right for
Solid Tumor
Revolution Medicines, Inc. 113
Testing effectiveness (Phase 2)Study completedNCT02352844
What this trial is testing

Everolimus in Patients With Advanced Solid Malignancies With TSC1, TSC2, NF1, NF2, or STK11 Mutations

Who this might be right for
Solid MalignancySolid Tumor
Washington University School of Medicine 12
Testing effectiveness (Phase 2)Ended earlyNCT05554354
What this trial is testing

Testing the Use of Fulvestrant and Binimetinib Targeted Treatment for NF1 Mutation in Hormone Receptor-Positive Metastatic Breast Cancer (A ComboMATCH Treatment Trial)

Who this might be right for
Anatomic Stage IV Breast Cancer AJCC v8Metastatic HER2-Negative Breast CarcinomaMetastatic Hormone Receptor-Positive Breast Carcinoma
National Cancer Institute (NCI) 1
Testing effectiveness (Phase 2)Active Not RecruitingNCT02407405
What this trial is testing

MEK 1/2 Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in Adults With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas

Who this might be right for
Neurofibromatosis 1 (NF1)Plexiform Neurofibromas (PN)
National Cancer Institute (NCI) 36
Testing effectiveness (Phase 2)Looking for participantsNCT06541847
What this trial is testing

A Phase 2, Open-Label Study to Evaluate the Safety and Effects of HLX-1502 in Patients With Neurofibromatosis Type 1

Who this might be right for
Neurofibromatosis Type 1
Healx Limited 25
Not applicableLooking for participantsNCT03893643
What this trial is testing

Cutaneous and Mucosal Manifestations of Neurofribromatosis Type 2 in Children Under 15

Who this might be right for
Neurofibromatosis 2Dermatology/Skin - Other
Centre Hospitalier Universitaire de Nice 1,000
Testing effectiveness (Phase 2)Looking for participantsNCT06188741
What this trial is testing

Selumetinib for the Prevention of Plexiform Neurofibroma Growth in NF Type 1

Who this might be right for
Neurofibromatosis 1Plexiform Neurofibroma
University of Alabama at Birmingham 200
Large-scale testing (Phase 3)Ended earlyNCT05130866
What this trial is testing

Efficacy and Safety of REC-2282 in Patients With Progressive Neurofibromatosis Type 2 (NF2) Mutated Meningiomas

Who this might be right for
Neurofibromatosis Type 2
Recursion Pharmaceuticals Inc. 25
Not applicableActive Not RecruitingNCT04759781
What this trial is testing

MElanoma Research Lymph Node Prediction Implementation National_001

Who this might be right for
Melanoma
SkylineDx 1,820
Testing effectiveness (Phase 2)Study completedNCT03433183
What this trial is testing

SARC031: MEK Inhibitor Selumetinib (AZD6244) in Combination With the mTOR Inhibitor Sirolimus for Patients With Malignant Peripheral Nerve Sheath Tumors

Who this might be right for
Malignant Peripheral Nerve Sheath TumorsNeurofibromatosis 1
Sarcoma Alliance for Research through Collaboration 21
Testing effectiveness (Phase 2)Ended earlyNCT00911248
What this trial is testing

PTC299 for Treatment of Neurofibromatosis Type 2

Who this might be right for
Neurofibromatosis 2
PTC Therapeutics 11
Not applicableStudy completedNCT07420751
What this trial is testing

Assessment of Patient Experience With Auto-Captioning Glasses in NF2-Related-Schwannomatosis

Who this might be right for
NF2-related Schwannomatosis
Massachusetts General Hospital 18
Next Page